Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sleep Apnea and Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03741647
Recruitment Status : Recruiting
First Posted : November 15, 2018
Last Update Posted : November 15, 2018
Sponsor:
Information provided by (Responsible Party):
Ahmad Abbas, Zagazig University

Brief Summary:
cases of locally advanced non small cell lung cancer (diagnosed by PET/CT scan and histopathological confirmation) will be screened for sleep disorders by Epworth sleepiness scale then confirmed by full night polysomnographic study. Blood sample to detect some genetic determinants will be withdrawn

Condition or disease Intervention/treatment
Locally Advanced Non Small Cell Lung Cancer Diagnostic Test: sleep study and blood sample

Layout table for study information
Study Type : Observational
Estimated Enrollment : 40 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Prognostic Significance of Sleep Apnea in Non Small Cell Lung Cancer
Actual Study Start Date : September 15, 2018
Estimated Primary Completion Date : September 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer


Intervention Details:
  • Diagnostic Test: sleep study and blood sample
    full night polysomnographic study and blood sample to detect some genetic issues


Primary Outcome Measures :
  1. Response to treatment [ Time Frame: 9 weeks from initiating therapy ]
    CT chest/pelvi-abdomen with contrast (evaluation using RECIST criteria)

  2. Response to treatment [ Time Frame: 18 weeks from initiating therapy ]
    CT chest/pelvi-abdomen with contrast (evaluation using RECIST criteria)


Secondary Outcome Measures :
  1. Progression Free Survival [ Time Frame: 3 months interval from ending therapy ]
    CT chest/pelvi-abdomen with contrast (evaluation using RECIST criteria)

  2. Progression Free Survival [ Time Frame: 6 months interval from ending therapy ]
    CT chest/pelvi-abdomen with contrast (evaluation using RECIST criteria)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
- patients with locally advanced non small cell lung cancer diagnosed, managed and followed up in clinical oncology department, zagazig university hospitals
Criteria

Inclusion Criteria:

  • patients with locally advanced non small cell lung cancer

Exclusion Criteria:

  • unable or refuse to perform sleep study
  • metastatic cases

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03741647


Contacts
Layout table for location contacts
Contact: Ahmad M Abbas, MD 201155355369 amabbaas@zu.edu.eg

Locations
Layout table for location information
Egypt
Ahmad Abbas Recruiting
Zagazig, Asharqia, Egypt, 44519
Contact: Ahmad M Abbas, MD    201155355369    amabbaas@zu.edu.eg   
Sponsors and Collaborators
Zagazig University

Layout table for additonal information
Responsible Party: Ahmad Abbas, Principal investigator &lecturer of chest disases zagazig university, Zagazig University
ClinicalTrials.gov Identifier: NCT03741647     History of Changes
Other Study ID Numbers: ZU-IRB #:4791/30-7-2018
First Posted: November 15, 2018    Key Record Dates
Last Update Posted: November 15, 2018
Last Verified: October 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms